NASDAQ:PROG - Progenity Stock Price Target and Predictions

  • Consensus Rating: Hold
  • Consensus Price Target: $5.33
  • Forecasted Upside: 96.08 %
  • Number of Analysts: 6
  • Breakdown:
  • 1 Sell Ratings
  • 2 Hold Ratings
  • 3 Buy Ratings
  • 0 Strong Buy Ratings
$2.72
▼ -0.28 (-9.33%)

This chart shows the closing price for PROG by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Progenity Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for PROG and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for PROG

Analyst Price Target is $5.33
▲ +96.08% Upside Potential
This price target is based on 6 analysts offering 12 month price targets for Progenity in the last 3 months. The average price target is $5.33, with a high forecast of $12.00 and a low forecast of $2.00. The average price target represents a 96.08% upside from the last price of $2.72.

This chart shows the closing price for PROG for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart

Current Consensus is Hold

The current consensus among 6 investment analysts is to hold stock in Progenity.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
4/28/2020
  • 0 strong buy ratings
  • 1 buy ratings
  • 2 hold ratings
  • 1 sell ratings
7/27/2020
  • 0 strong buy ratings
  • 2 buy ratings
  • 2 hold ratings
  • 1 sell ratings
10/25/2020
  • 0 strong buy ratings
  • 2 buy ratings
  • 2 hold ratings
  • 1 sell ratings
1/23/2021
  • 0 strong buy ratings
  • 2 buy ratings
  • 2 hold ratings
  • 1 sell ratings
4/23/2021
  • 0 strong buy ratings
  • 2 buy ratings
  • 2 hold ratings
  • 1 sell ratings
7/22/2021
  • 0 strong buy ratings
  • 2 buy ratings
  • 2 hold ratings
  • 1 sell ratings
9/20/2021
  • 0 strong buy ratings
  • 3 buy ratings
  • 2 hold ratings
  • 1 sell ratings
10/20/2021

Latest Recommendations

  • 0 strong buy ratings
  • 3 buy ratings
  • 2 hold ratings
  • 1 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
10/14/2021HC WainwrightInitiated CoverageBuy$4.00High
7/29/2021Piper SandlerBoost Price TargetOverweight$3.00 ➝ $5.00High
6/3/2021Piper SandlerLower Price TargetOverweight$8.00 ➝ $3.00High
6/3/2021Robert W. BairdDowngradeOutperform ➝ Neutral$4.00 ➝ $2.00High
6/2/2021Raymond JamesDowngradeOutperform ➝ Market PerformHigh
5/17/2021Wells Fargo & CompanyLower Price TargetUnderweight$4.00 ➝ $2.00High
5/14/2021Raymond JamesLower Price TargetOutperform$10.00 ➝ $7.00High
5/14/2021Robert W. BairdLower Price TargetOutperform$6.00 ➝ $4.00Medium
3/21/2021Robert W. BairdReiterated RatingBuy$6.00Low
2/8/2021Wells Fargo & CompanyDowngradeOverweight ➝ Underweight$5.00High
1/14/2021Piper SandlerLower Price TargetOverweight$15.00 ➝ $10.00High
11/10/2020Raymond JamesLower Price TargetOutperform$15.00 ➝ $10.00High
11/10/2020Piper SandlerLower Price TargetAverage ➝ Overweight$17.00 ➝ $15.00High
10/23/2020BTIG ResearchInitiated CoverageBuy$12.00Low
8/19/2020Raymond JamesReiterated RatingBuyHigh
7/14/2020Piper SandlerInitiated CoverageOverweight$17.00High
7/14/2020Robert W. BairdInitiated CoverageOutperform$12.00Medium
7/14/2020Raymond JamesInitiated CoverageOutperform$15.00High
7/14/2020Wells Fargo & CompanyInitiated CoverageOverweight$11.00High
(Data available from 10/20/2016 forward)

News Sentiment Rating

0.63 (Buy)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 0 very positive mentions
  • 6 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
3/24/2021
  • 0 very positive mentions
  • 2 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
4/23/2021
  • 0 very positive mentions
  • 7 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
5/23/2021
  • 0 very positive mentions
  • 7 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
6/22/2021
  • 0 very positive mentions
  • 6 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
7/22/2021
  • 7 very positive mentions
  • 12 positive mentions
  • 3 negative mentions
  • 0 very negative mentions
8/21/2021
  • 2 very positive mentions
  • 10 positive mentions
  • 1 negative mentions
  • 1 very negative mentions
9/20/2021
  • 8 very positive mentions
  • 27 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
10/20/2021

Current Sentiment

  • 8 very positive mentions
  • 27 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Progenity logo
Progenity, Inc., a biotechnology company, provides develops and commercializes molecular testing products in the United States. It offers Innatal, a noninvasive prenatal screening test offered to women early in pregnancy to screen for chromosome abnormalities, such as down syndrome, trisomy 18, trisomy 13, and sex chromosome disorders through the analysis of cell-free DNA; Preparent that screens for carrier status of hereditary diseases prior to or early in pregnancy; and Riscover, a hereditary cancer screen that analyzes 31 genes associated with inherited risk of 12 types of cancers, including the BRCA1/2 genes for hereditary breast, ovarian, colorectal, endometrial, pancreatic, and other cancer syndromes, as well as for the five genes associated with Lynch syndrome. The company also provides Resura, a noninvasive prenatal test for families at risk for rare single gene disorders; and Preecludia, a preeclampsia rule-out test. In addition, it offers anatomic and molecular pathology tests, and COVID-19 PCR testing services, as well as test products that includes chromosomal microarray for pregnancy loss, which evaluates the genetic cause of miscarriage; maternal serum screening for chromosomal disorders; and preimplantation genetic testing for use with artificial reproductive technologies. Further, the company develops therapeutic solutions for gastrointestinal-related disorders, such as PGN-001, PGN-300, PGN-600, and PGN-OB2. It also owns and operates laboratory. Progenity, Inc. was formerly known as Ascendant MDX, Inc. and changed its name to Progenity, Inc. in November 2013. The company was founded in 2010 and is headquartered in San Diego, California.
Read More

Today's Range

Now: $2.72
Low: $2.66
High: $2.92

50 Day Range

MA: $1.29
Low: $0.67
High: $2.99

52 Week Range

Now: $2.72
Low: $0.66
High: $8.57

Volume

71,267,992 shs

Average Volume

15,089,383 shs

Market Capitalization

$215.98 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

N/A

Frequently Asked Questions

What sell-side analysts currently cover shares of Progenity?

The following Wall Street sell-side analysts have issued reports on Progenity in the last year: BTIG Research, HC Wainwright, Piper Sandler, Raymond James, Robert W. Baird, Wells Fargo & Company, and Zacks Investment Research.
View the latest analyst ratings for PROG.

What is the current price target for Progenity?

6 Wall Street analysts have set twelve-month price targets for Progenity in the last year. Their average twelve-month price target is $5.33, suggesting a possible upside of 77.8%. BTIG Research has the highest price target set, predicting PROG will reach $12.00 in the next twelve months. Wells Fargo & Company has the lowest price target set, forecasting a price of $2.00 for Progenity in the next year.
View the latest price targets for PROG.

What is the current consensus analyst rating for Progenity?

Progenity currently has 1 sell rating, 2 hold ratings and 3 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Hold." A "hold" rating indicates that analysts believe investors should keep any existing positions they have in PROG, but not buy more shares or sell existing shares.
View the latest ratings for PROG.

What other companies compete with Progenity?

How do I contact Progenity's investor relations team?

Progenity's physical mailing address is 4330 LA JOLLA VILLAGE DRIVE SUITE 200, SAN DIEGO CA, 92122. The official website for Progenity is www.progenity.com.